SI-BONE to Present at the Canaccord Genuity 41st Annual Growth Conference

SI-BONE, Inc. (Nasdaq: SIBN), a leader in musculoskeletal disorder solutions, announced its participation in the Canaccord Genuity 41st Annual Growth Conference on August 11 at 3:30 p.m. ET.

Rhea-AI Summary

SI-BONE, Inc. (Nasdaq: SIBN), a leader in musculoskeletal disorder solutions, announced its participation in the Canaccord Genuity 41st Annual Growth Conference on August 11 at 3:30 p.m. ET. This event will showcase SI-BONE's innovations, particularly the iFuse Implant System, designed for minimally invasive surgeries targeting SI joint pain, a contributor to chronic low back pain affecting up to 30% of patients. More than 55,000 SI joint fusion procedures have been performed using this technology. Live access to the presentation will be available on the company’s website.

Argus Session date unavailable

+0.57% session move Open Argus

Details

News Market Reaction – SIBN

The recorded move for SIBN in the trading session of this news was +0.57%.

Data tracked by StockTitan Argus. Session date unavailable.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

SANTA CLARA, Calif., July 29, 2021 (GLOBE NEWSWIRE) -- SI-BONE, Inc. (Nasdaq: SIBN), a medical device company dedicated to solving musculoskeletal disorders of the sacropelvic anatomy, today announced that the company will be participating in the upcoming Canaccord Genuity 41^st Annual Growth Conference. Management is scheduled to present on Wednesday, August 11 at 3:30 p.m. Eastern Time / 12:30 p.m. Pacific Time.

Interested parties may access a live and archived webcast of the presentation on the “Investors” section of the company’s website at: www.si-bone.com

About SI-BONE, Inc.
SI-BONE (NASDAQ: SIBN) is a global leader in technology for surgical treatment of musculoskeletal disorders of the sacropelvic anatomy. In 2009, SI-BONE introduced the iFuse Implant System for minimally invasive surgery of the SI joint, shown to be a source of pain in 15% to 30% of chronic low back pain. Since then, more than 2,400 surgeons have performed a combined total of more than 55,000 SI joint fusion procedures. A unique body of evidence, supporting the iFuse Implant System, including two RCT’s and over 95 peer reviewed publications, has enabled multiple government and private insurance payors to establish coverage of the SI joint fusion procedure exclusively when performed with the iFuse Implant System. SI-BONE is leveraging its market leadership position, supported by this proprietary reimbursement advantage, to commercialize other devices intended for surgical treatment of related aspects of the human anatomy. For more information or to join our team, please visit us at www.si-bone.com.

For additional information on the company or the products including risks and benefits, please visit www.si-bone.com.

SI-BONE and iFuse Implant System are registered trademarks of SI-BONE, Inc. ©2021 SI-BONE, Inc. All Rights Reserved.

Investor Contact:
Matt Bacso, CFA
investors@SI-BONE.com

Media Contact:
Joe Powers
jpowers@si-bone.com

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

When will SI-BONE participate in the Canaccord Genuity 41st Annual Growth Conference?

SI-BONE will present at the Canaccord Genuity 41st Annual Growth Conference on August 11 at 3:30 p.m. Eastern Time.

How can I access the SI-BONE conference presentation?

The presentation can be accessed live and archived on SI-BONE's website in the 'Investors' section.

What is the significance of the iFuse Implant System for SI-BONE?

The iFuse Implant System is crucial for SI-BONE as it addresses SI joint pain, a major factor in chronic low back pain, and has supported over 55,000 fusion procedures.

What percentage of chronic low back pain is attributed to SI joint issues?

SI joint issues are known to contribute to 15% to 30% of chronic low back pain.